The drug uses albumin technology from Novozymes to extend the drug's presence in the patient's body.
Many injected treatments require daily dosing, which can be challenging for patients.
Pharma companies are therefore seeking to develop longer lasting drugs that allow patients to dose less frequently.
Known as VELTIS, the Novozymes technology that extends the active drug lifespan is based on albumin, a naturally occurring protein that can be found in human blood.
"The first approval for a product based on Novozymes' VELTIS technology, and marketed by one of the largest pharmaceutical companies in the world, marks a significant milestone for our half-life extension technology", said Mr Thomas Videbæk, executive vice president, Novozymes. "We consider this authorization as a real proof that VELTIS can offer true benefits to patients, reducing the inconvenience associated with daily drug dosing."